Speeding up heart science: How Boehringer Ingelheim is streamlining data analysis in the lab
A cardiovascular researcher at Boehringer Ingelheim describes how cutting through data complexity has given her something rare in modern science: time back at the bench.
Ines Gigler uses JMP to simplify data integration, eliminate manual errors, and unlock deeper insights across cardiovascular experiments. By reducing analysis time from 3–4 hours to minutes, JMP enables more time in the lab and accelerates progress toward new therapies.
In our latest customer success story, Ines Gigler, a cardiovascular research scientist at Boehringer Ingelheim, highlights how JMP is transforming day-to-day scientific workflows in a global biopharmaceutical environment. Despite the company’s scale, its research culture emphasizes innovation, integrity, and long-term value, making efficiency and data quality critical to success.
In the cardiorenal metabolic research group, Gigler studies mechanisms of heart disease by simulating cardiac cell behavior in the lab. Previously, fragmented workflows involving Excel, CSV files, and manual copy-paste processes introduced delays and frequent errors, sometimes requiring entire analyses to be restarted. With JMP, these challenges have been replaced by a seamless workflow that integrates multiple data sources, automates preparation steps, and enables rapid, interactive analysis.
The impact is significant: analysis time has been reduced from hours to minutes, data accuracy has improved dramatically, and researchers can now explore full datasets rather than sampling specific time points. Visual tools such as Graph Builder, along with reusable workflows, have enhanced collaboration and decision-making across teams. Ultimately, JMP is not just saving time; it is enabling scientists to focus on what matters most: advancing research that improves patient outcomes.
Return on Investment (ROI)
- ~85–90% reduction in analysis time (hours reduced to minutes or seconds).
- Significant reduction in rework caused by undetected data errors.
- Increased experimental throughput due to more time spent in the lab.
- Higher-quality decision-making through access to complete datasets and interactive visualization.
- Improved collaboration efficiency, reducing back-and-forth between researchers and managers.
Keywords
Boehringer Ingelheim, JMP, cardiovascular research, data analysis, workflow automation, life sciences, biopharmaceutical innovation, research efficiency, data visualization, Graph Builder, experimental design, lab productivity, scientific discovery, healthcare innovation
Great story, and a nice example for our prospects/customers working with plate analysis data. Going from 3-4h to 30 minutes analysis is a big advantage
Another great story, Love that "Dont be afraid, just start using JMP!"
And here is her poster from EMEA Discovery Summit 2026 highlighting these keypoints:
https://community.jmp.com/t5/Abstracts/A-New-Exploratory-Data-Analysis-Approach-in-Cardiovascular/ev-p/916557
The conclusion is public and a strong argument. Those research groups have many (potential JMP) users, great for an upgrade. It is also a great example how an advocate can help to access those groups (see acknowledgements).
THanks @Natalie and team for making this happen 
